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Nitric oxide mediates renal vasodilation during erythropoietin-lnduced
polycythemia. The renal blood flow (RBF) of patients with polycythemia
rubra vera is increased despite the high hematocrit (Hct) which elevates
the whole blood viscosity. Since blood viscosity determines the shear
force on the endothelium which is a major stimulus to nitric oxide (NO)
release, we investigated the hypothesis that renal vasodilation during
erythropoietin-induced erythrocytosis is mediated by the L-argi-
nine-NO pathway. Groups of Sprague-Dawley rats received thrice
weekly injections of crythropoietia (E) for two to five weeks; responses
were contrasted with normal rats (N) which received sham injections.
The first group was studied after five weeks of erythropoietin injections
which led to sharp increases in Hct (B: 72 3 vs. N: 44 1%) and mean
arterial pressure (MAP: 126 3 vs. 107 3 mm Hg). These rats had an
elevated basal RBF whether measured by the clearance and renal
extraction of PAH or by a transit-time renal blood flow meter. Subse-
quent groups were studied after two to three weeks of erythropoietin
which raised the Hct more modestly to 59 2%. In this group, the basal
MAP was similar in B and N rats. Graded doses of the NO synthase
inhibitor, N'-moaomethyl-L-argithne (L-NMA) led to a steeper rise in
MAP in E than N; at the highest doses, the MAP had increased by 36
2 in B and 23 3 mm Hg in N (P < 0.01). Therefore, to assess the
effects of L-NMA on renal vascular resistance without the confounding
effects of differences in MAP, the renal perfusion pressure (RPP) was
controlled with a suprarenal aortic clamp. In the basal state, the RBF
was higher in F than N (F: 5.33 0.54 vs. N: 3.85 0.28
ml' min' 100 g'; Pc 0.025). L-NMA caused a greater reduction in
RBF, and a greater rise in filtration fraction (FE) and renal vascular
resistance (RVR) in erythropoietin-treated rats. During L-NMA, the
RBF became similar in the two groups (F: 2.19 0.50 vs. N: 2.42
0.32 ml min' 100 g'; NS). We conclude that an enhanced genera-
tion of NO from L-arginine maintains normotension and mediates renal
vasodilation in rats with erythropoietin-induced erythrocytosis.
In vitro studies have shown that the hematocrit (Hct) is the
major determinant of whole blood viscosity which increases
exponentially with Hct values above the physiologic range [1,
21. Indeed, increases in the Hct of blood perfusing a dog's hind
limb preparation [3] or an isolated perfused dog's kidney [4] in
which active vasomotor changes are prevented, reduce blood
flow. In contrast, an abrupt increase in the Hct of blood
perfusing a dog's kidney in which vasomotor changes are intact
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does not change the RBF in the short-term [4]. Moreover,
studies of human subjects with polycythemia rubra vera show
that the REF is greatly increased despite Hct values above 65%
[5]. These findings imply that a rise in the Hct causes vasodi-
lation of the renal circulation sufficient to maintain the REF in
the short-term or to raise it above basal levels in the long term.
The mediator of this renal vasodilation has not been deter-
mined.
The basal release of endothelium-derived nitric oxide
(EDNO) is determined by vessel wall shear stress [6, 7].
Release of NO within the kidney is a major determinant of the
basal REF [8]. Therefore, we investigated the hypothesis that
the L-arginine-NO pathway is activated during sustained eryth-
ropoietin-induced polycythemia and mediates the ensuing va-
sodilation. We compared the response to N'°-monomethyl-L-
arginine (L-NMA) which blocks NO synthase in groups of
erythropoietin-treated and normal rats.
Methods
Animal preparation
Experiments were performed on male Sprague-Dawley rats
weighing 200 to 250 g. Animals received three subcutaneous
injections weekly. Animals destined for polycythemia received
erythropoietin (300 IU kg—'; Epogen), whereas the normal
control rats received sham injections. For the first series, rats
were studied after developing severe polycythemia (Hct 70 to
75%) after five weeks of erythropoietin administration. For the
subsequent series, animals were studied with less severe poly-
cythemia (Hct 55 to 65%) after two to three weeks of erythro-
poietin administration. Rats were maintained on standard rat
chow (Rodent Laboratory Chow, 5001, Ralston-Purina, Co., St.
Louis, Missouri, USA).
On the experimental day, rats were anesthetized with mactin
(100 mg kg' i.p.; BYK, Gulden, Konstanz, Germany). They
were prepared for renal clearance and/or blood pressure mea-
surements [9]. About 10% of the rats which had received
erythropoietin were found to have a Hct below 55%. These
animals were not studied. For the remainder, a euvolemic state
was maintained by infusion of albumin (6 g d1'; Sigma
Chemical Co., St. Louis, Missouri, USA), dissolved in 0.145 K!
NaCl solution at 0.5 ml' 100 g body w' hC' following a
priming dose of 0.5 ml. The bladder was cannulated to collect
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urine. One femoral artery was cannulated to measure the mean
arterial pressure (MAP) or the renal perfusion pressure (RPP).
Both jugular veins were cannulated. For clearance studies, one
transmitted an infusion of [3HJ-inulin (0.1 pCi kg 1 hr 1) and
['4C]-paraaminohippurate (PAH; 0.05 pCi kg' hr1; both
supplied by New England Nuclear, Boston, Massachusetts,
USA) which were added to the maintenance infusion of albumin
and saline. The other was maintained patent with heparin and
saline and was used to infuse vehicle or drugs. The GFR was
taken as the clearance of inulin and the renal plasma flow (RPF)
as the clearance of PAH.
Rats of group 3 were prepared for control of the renal
perfusion pressure (RPP). The aorta was cleared of connective
tissue and dissected free of the posterior abdominal wall. A
clamp was placed around the aorta cephalad of the renal
arteries. The RPP was recorded from the cannulated femoral
artery and was regulated by adjusting the screw clamp [9].
Protocols
The aim of the first series was to determine the effects of a
severe elevation of Hct on MAP and RBF and to validate the
PAH clearance method used to measure RPF in polycythemic
rats. Rats were studied after five weeks of erythropoietin
injections. They were prepared for simultaneous studies of
PAH clearance and extraction and for transit-time RBF mea-
surements. A flow probe (1 mm ID) was placed around the left
renal artery and the left renal vein was visualized for puncture.
The flow probe was connected to a transit-time blood flow
meter (Transonics, Inc., Ithaca, New York, USA). Thirty
minutes after completion of surgery, there was a 30-minute
clearance period while RBF was recorded each five minutes
with the flow meter; these data were averaged. At the beginning
and the completion of the period, blood was sampled from the
femoral artery and the renal vein by venipuncture using a 27
gauge stainless steel needle connected to a syringe mounted on
a micromanipulator (Hawksley, Inc., England, UK). The nee-
dle was directed toward the kidney. Care was taken to prevent
aspirating blood back from the inferior vena cava. Five eryth-
ropoietin-treated rats and six normal rats were studied. Subse-
quent studies were undertaken in rats with a less severe
elevation of Hct after two to three weeks of erythropoietin
administration.
The aim of the second series was to investigate the effects of
polycythemia on the MAP responses to inhibition of NOS with
L-NMA. These rats were prepared for measurement of BP but
not for clearance. After a basal period of 30 minutes with
measurement of MAP and Hct, rats received intravenous doses
of L-NMA (1,3,10,30 and 100 mg kg'). The MAP was re-
corded five minutes after each bolus, corresponding to the
period of maximal rise in BP. After the highest dose, L-arginine
(500 mg kg' i.v.) was administered and the MAP recorded 5
to 10 minutes later. In each rat, L-arginine reduced the BP to,
or below, the basal level. A dose-response relationship was
constructed for changes in MAP with L-NMA.
The aim of the third series was to investigate the effects of
polycythemia on the renal hemodynamic response to L-NMA.
Since we had found that polycythemic rats had a steeper
increment in MAP during NOS inhibition, differences in renal
hemodynamic responses to NOS inhibition might relate to
differences in RPP. Therefore, for this series, the RPP was
controlled at basal values throughout by adjusting a suprarenal
aortic clamp. Therefore, changes in RBF reflect reciprocal
changes in RVR. Clearance measurements were made in the
basal period and 15 to 45 minutes after the administration of
L-NMA (30mg kg and 15 mg kg' . hr'). In each period,
blood was drawn at the mid-point.
The aim of the fourth series was to investigate the effects of
polycythemia on the excretion of cyclic guanosine monophos-
phate (cGMP). Six polycythemic rats received erythropoietin
for two to three weeks. Results were compared with six normal
rats. Under anesthesia, urine was collected in the basal state,
frozen at —70°C and subsequently assayed for cGMP using an
ELISA method (Cayman Chemical Co., Ann Arbor, Michigan,
USA). The rate of excretion of cGMP was factored by GFR
[10].
Drugs
Erythropoietin injection (Epogen) was obtained from Amgen,
Inc. (Thousand Oaks, California, USA). L-NMA, L-NAME
and L-arginine were obtained from Sigma Chemical Corpora-
tion and dissolved in 0.145 M NaCl solution prior to use.
Statistics
Mean SEM values were calculated for groups of polycythe-
mic and normal rats. Between group analyses were performed
by two tailed Student's t-tests. Data were considered statisti-
cally significant at P < 0.05.
Results
Rats that received erythropoietin appeared fit and healthy.
They grew by 5 to 7 g 24 hr' which is the expected weight
gain. None of the rats died prior to sacrifice.
The first series served to establish a model of erythropoietin-
induced erythrocytosis and to investigate appropriate methods
for measuring renal blood flow (RBF) in such rats. Rats that had
received erythropoietin injections for five weeks were com-
pared to normal control rats. Both groups were prepared for
renal clearance of [14C]-PAH with renal vein puncture for
measurement of the renal ['4C]-PAH extraction (EPAH). The
renal blood flow was calculated from the clearance and extrac-
tion of PAH and the Hct. Simultaneous measurements were
made of RBF from a transit-time blood flow meter. Results are
shown in Table 1. With this five week protocol of erythropoietin
administration, rats studied under anesthesia had a severe rise
in hematocrit to 72 3% accompanied by a consistent increase
in MAP. EPAH was similar in both groups and was similar to
results reported previously [11]. The RBF, whether measured
from the clearance and extraction of PAH corrected for Hct or
from the transit-time blood flow meter was significantly in-
creased in the erythropoietin-injected rats. Values recorded by
the two techniques were not significantly different whether
analyzed for the entire group or for normal or erythropoietin-
treated rats separately. The EPAH was measured in a further
subgroup of eight normal rats before and during an infusion
of N-nitro-L-arginine methyl-esther (L-NAME) at 1 mg
kg min1. EPAH was not consistently altered (basal: 72 6
vs. L-NAME: 78 4%; NS). We conclude: first, that this
schedule of erythropoietin injections over five weeks produced
a very severe increase in Hct with a rise in MAP. Therefore, the
subsequent protocols used a shorter schedule of injections
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Table 1. Basal data for blood pressure and renal blood flow calculated from PAN clearance and extraction and Net or transit-time blood flow
meter records in normal and polycythemic rats of group I
RBF from transit-
RBF from CPAH, time blood flow
Group
Number
of rats Hct % MAP EPAM %
EPAN and Hct meter
ml mi,r' 100 g'
Normal 6 44±1 107±3 70±5 3.03±0.24 3.11±0.16
Erythropoietin 5 72 3 126 3 71 6 4.50 0.60 4.01 0.18
P value <0.001 <0.001 NS <0.05 <0.005
Data are mean SEM. Erythropoietin was administered for S weeks.
which produced a less severe increase in Net unaccompanied
by a rise in MAP. Second, CPAH appeared to be a valid marker
for contrasting renal blood flow dynamics in erythropoietin-
treated rats. Since the renal vein puncture altered renal function
in some rats, EPAH was not measured in subsequent protocols.
The aim of group 2 was to study the BP response to graded
blockade of NOS with intravenous bolus doses of L-NMA. The
response of 13 normal rats (weight 271 18 g) were contrasted
with nine rats that had received erythropoietin for two to three
weeks (weight 277 13 g). The Hct was increased in those that
had received erythropoietin (E: 58 1 vs. N: 47 1%; P <
0.001). The mean arterial pressure at baseline was similar in the
two groups (E: 119 3 vs. N: 113 4 mm Hg; NS). L-NMA,
in the range of 3 to 100 mg kg1 raised MAP progressively in
both groups. As shown in Figure 1, erythropoietin-injected rats
had a significantly enhanced pressor response to L-NMA at
doses of 10 mg kg1 and above. At the highest dose studied,
the increment of MAP in polycythemic rats of 36 2 mm Hg
was 56% above that of the normal rats which averaged 23 3
mm Hg.
The aim of group three was to study the effect of inhibition of
NOS on renal hemodynamics in groups of normal and erythro-
poietin-treated rats at comparable levels of RPP. The basal data
and the response to infusion of L-NMA during regulation of
RPP are shown in Table 2. In the basal state, the suprarenal
aortic clamp was not engaged. The renal perfusion pressure was
similar in the two groups. The erythropoietin-injected rats had
similar values for GFR, RPF (measured without correction for
EPAH) and filtration fraction (FF). However, E rats had a 38%
increase in RBF and a corresponding reduction in RVR. During
infusion of L-NMA, the RPP was maintained in both groups by
adjusting the suprarenal aortic clamp. There was a sharp and
comparable fall in GFR in both groups accompanied by a
proportionately greater fall in RPF resulting in an increase in
FF. The rise in FF was greater in the erythropoietin-injected
rats due to a rather greater fractional change in RPF (E: —59
6 vs. N: —42 5%; P < 0.05). During infusion of L-NMA, the
RBF became strictly comparable in both groups. This resulted
from a significantly greater decline in RBF with L-NMA in the
erythropoietin-injected rats. The individual values for L-NMA-
induced changes in RBF are shown in Figure 2. It is apparent
that the polycythemic animals had a greater absolute and
fractional reduction in RBF with L-NMA although there was
overlap between the two groups.
The aim of group four wns to contrast the excretion of eGMP
in control and erythropoietin-induced rats. A group of six
normal and six polycythemic rats were studied. As shown in
Figure 3, the excretion of cGMP factored by GFR was clearly
elevated in the polycythemic animals.
Discussion
The present study describes rat models of moderate and
severe erythropoietin-induced erythrocytosis accompanied by
increased RBF. During prolonged administration of erythropoi-
etin, the results of two independent methods based on PAN
clearance and extraction or transit-time blood flow concurred in
showing an increase in RBF. However, it was not clear whether
this increase in RBF was due to a breakdown of renal autoreg-
ulation in these polycythemic rats which had an elevated BP.
However, when studied at an earlier stage of polycythemia, rats
were again found to have an increase in basal RBF but the BP
was similar. This implies that these polycythemic rats had
vasorelaxation of the renal resistance vessels compared to the
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Fig. 1. Mean SEM values for changes in mean arterial pressure with
increasing bolus doses of L-NMA in groups of normal (0) and
polycythemic (•) rats of series 2 (Hct 55 to 65%). Compared to normal:
* P <0.05; ** P < 0.01.
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Table 2. Blood pressure and renal hemodynamics in normal and erythropoietin-treated rats of group 3 before and during infusion of L-NMA
with control of renal perfusion pressure
Number Hct
Group of rats %
RPP mm Hg GFR ml min' 100 g'
Before
During
L-NMA ABefore
During
L-NMA A
Normal 13 42 1
Erythropoietin 8 59 2
P value <0.001
117 4
119 5
NS
116 3 —l
121 4 +2
NS NS
1
1
0.57 0.05
0.48 0.05
NS
0.37 0.05 —0.20 0.06C
0.28 0.07 —0.19 0.06C
NS NS
Table 2. Continued
RPFmlmin '100g' FF% RBFmlmin'100g'
During
Before L-NMA A Before
During
L-NMA A
During
Before L-NMA A
2.41 0.21 1.40 0.19 —1.00 0.24C 23.9 1.4 27.5 1.3 +3.5 12b 3.85 0.28 2.42 0.32
2.10 0.39 0.91 0.26 —1.19 0.20C 25.6 3.2 33.9 2.1 +8.3 l.8C 5.33 0.54 2.19 0.50
NS NS NS NS <0.025 <0.05 < 0.025 NS
—1.43 0.27c
—3.14 0.40'
<0.005
Data are mean SEM. Erythropoietin was administered for 2 to 3 weeks. Data were obtained before and during intravenous infusion of L-NMA(30mg kg' and 15 mg kg' hr') in rats of series 3.
Significance of change during infusion of L-NMA: a p < 0.05, b p < 0.01, C p < 0.005
control rats. Indeed, the increase in RBF occurred despite an
increase in Hct which should raise the whole blood viscosity.
Erythropoietin administration to rats [12] or human subjects
with renal failure [13] does not change the plasma renin activity
but, in the rat, it increases the expression of mRNA for renin
and renin substrate in the kidney. Therefore, the renal vasodi-
latation of rats which had received erythropoietin is not likely to
be mediated by a reduced renal Ang II generation.
Rises in Hct above the physiologic range produce sharp
increases in blood viscosity whether measured by a viscometer
in vitro or from the relationship between pressure and flow in
vivo [1—3]. However, the precise contribution of Hct to blood
viscosity in vivo cannot be predicted from in vitro studies
because of differences in the systemic and microvascular Hct
[14], the Fahraeus-Lindquist effect [15],the effect of vessel wall
shear stress on Hct-induced changes in viscosity [16] and the
contribution of other blood cell constituents [14]. Nevertheless,
when autoregulatory adjustments are prevented, increases in
hematocrit are accompanied by sharp reductions in blood flow
through the hindlimb [1, 3], or the kidney [4] of the dog, the ear
of the rabbit [16], or the mesentery of the cat [14]. Therefore,
the finding of an increased RBF at an elevated Hct during
erythropoietin administration implies substantial renal vasodi-
latation. Indeed, studies in human subjects with polycythemia
rubra vera have documented some of the highest values for
RBF recorded in man; treatment of the polycythemia reduces
the RBF to normal levels [5]. Some patients with polycythemia
complicating chronic hypoxemia also have a reduction in RBF
after correction of the polycythemia although, in this group,
basal values of RBF are not elevated perhaps because of the
effects of cor pulmonale and heart failure [17, 18].
The BP is normally quite well maintained after short-term [4]
and long-term [19] changes in Hct above and below the normal
range produced by exchange transfusion of packed cells or
plasma into normal animals. Erythropoietin can increase the
systolic BP of normal conscious rats but the effect is quite
modest and is independent of changes in Hct [12]. Patients with
polycythemia rubra vera usually do not have hypertension.
Nevertheless, animal studies have shown that an increase in
Hct leads to an increase in the peripheral vascular resistance
P<0.005 B P<0.025
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Fig. 2. Individual values for absolute (A) and
fractional (B) changes in renal blood flow
during infusion of L-NMA in normal and
polycythemic rats of series 3 (Hct 55 to 65%).
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Fig. 3. Mean SEAt values for excretion of cyclic GMF factored by
GFR in groups of normal and polycythemic rats of series 4 (Hct 55 to
65%).
and a matching reduction in the cardiac output sufficient to
maintain the BP [19]. In contrast, an increase in Hct leads to an
increase in BP in animal models of hypertension [20, 21]. In
human hypertensive subjects, there is a direct correlation
between blood viscosity or Hct and BP [22—25]. Administration
of erythropoietin to patients with chronic renal failure can
exacerbate hypertension [26]. Results of the present study show
that modest erythrocytosis (Hct 55 to 65%) induced by eryth-
ropoietin administered to normal rats does not raise BP when
measured under anesthesia despite the rise in calculated blood
viscosity. This implies either that there has been reciprocal and
balanced changes in cardiac output and peripheral resistance,
or that the effects of increased blood viscosity are offset by
vasodilatation. More prolonged administration of erythropoie-
tin that raised the Hct to 70 to 75% induced a consistent
increase in MAP of rats when measured under anesthesia. This
suggests that the autoregulatory adjustments to high Hct can be
exhausted even in normal rats under extreme conditions of
polycythemia.
Graded doses of L-NMA given to rats with modest erythro-
cytosis and normal resting MAP led to an exaggerated rise in BP
which was reversed by L-arginine. The exaggerated pressor
response to L-NMA in polycythemia implies that polycythemia
has activated NOS and enhanced the generation of NO. This
may be a consequence of the sustained increase in vessel wall
shear stress. Hypertension decreases endothelial NO produc-
tion which might therefore account for the failure of these
hypertensive subjects or animals to maintain normal BP in the
face of increased Hct.
It has been suggested that hypertension associated with
erythropoietin therapy is due to trapping of NO produced by
endothelial cells by the high levels of hemoglobin in the blood
stream [28]. However, our results indicate that there is an
excessive action of NO on blood vessels and the kidney in this
rat model of erythropoietin-induced polycythemia. There may
be a sufficient increase in NO production to offset the potential
trapping of NO in polycythemic blood.
The kidney mounts a unique circulatory adjustment to eryth-
rocytosis. Immediately after an exchange transfusion of eryth-
rocytes to raise the Hct in the dog [4] or rat [291, the RBF or
glomerular blood flow declines. Micropuncture studies in the
rat show that there is an increase in total renal vascular
resistance due predominantly to a rise in efferent arteriolar
resistance [29]. This could be a passive response to an increase
in blood viscosity. Such an effect should be most marked in the
efferent arteriole, which contains blood with an elevated Hct
and plasma protein concentration due to the effect of filtration
by the upstream glomerular capillaries. However, in the dog or
rat, the REF is restored to basal values [4, 12, 13, 30, 31] or
above [32] over 30 to 60 minutes after an abrupt increase in Hct.
Dogs with sustained polycythemia due to repeated exchange
transfusions with packed erythrocytes have a progressive in-
crease in RBF of 40 to 60% above basal levels over two weeks.
This is sufficient to restore the RPF [33]. In the rat, the GFR is
reduced immediately following exchange transfusion with
erythrocytes [29] but thereafter is restored to basal levels [12,
30, 33, 34]. The present study shows that prolonged polycythe-
mia in the rat leads to a substantial increase in the RBF with
preservation of the GFR. Chronic polycythemia in man is
associated with increased RBF [5]. This specific renal vasodi-
lator response to chronic polycythemia may represent engage-
ment of unique renal autoregulatory mechanisms such as the
tubuloglomerular feedback response that maintains the GFR
[34]. The tubuloglomerular feedback response itself is modu-
lated by release of NO from the macula densa [35]. However,
the role of tubuloglomerular feedback in Hct-induced changes
in RBF has not been studied. The present findings show that
enhanced NO generation is required for the increased RBF in
polycythemia since L-NMA reduced REF to a greater extent in
polycythemic rats; after L-NMA, there was no longer a differ-
ence in RBF between normal and polycythemic rats. The
predominant site of intrarenal action of NO in this erythropoi-
etin model of polycythemia cannot be established precisely
from clearance measurements. However, L-NMA caused a
greater rise in FF and RVR in the polycythemic animals,
suggesting that endogenous production of NO may contribute
to vasorelaxation of the afferent, and especially the efferent,
arterioles.
The excretion of cyclic GMP, factored by GFR, was in-
creased in polycythemic rats. An increase in cGMP excretion
has been used as an index of the renal actions of NO on soluble
guanylate cyclase or of atrial natriuretic peptide on particulate
guanylate cyclase [10]. It is possible that both these systems are
activated in chronic polycythemia due to the combined effect of
an expanded blood volume and an enhanced vessel wall shear
stress. Together they may coordinate the renal circulatory
adjustments to polycythemia that maintain the GFR despite the
increase in blood viscosity and the reduced fluid fraction of
blood flowing through the renal vessels.
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